Featured

Outsourced Pharma Capacity Update October 2025: Cell & Gene Therapy

Fulfilling The Promise Of Advanced Therapies And A Noble Cause

Rethinking Lentiviral Manufacturing for Cell and Gene Therapies: from Platform Design to Point-of-care Delivery

Strategies for Efficiency and Affordability in Cell and Gene Therapy

Vector BioMed COO Mike Kadan on Reinventing Viral Vector Manufacturing for a Decentralized Gene Therapy Future

Global Access to Cell and Gene Therapy: ARM Studios Interview with Boro Dropulić

Boro Dropulić: Simplifying CAR-T workflows will break down barriers to patient access

Scroll to Top